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Background
The history of the world citrus industry is marked by a
series of diseases caused by different etiologic agents.
Several of them are characterized as biotrophic patho-
gens like Xanthomonas citri subsp. citri, three Candida-
tus Liberibacter spp and Citrus leprosis virus C (CiLV-C).
In plant-pathogen interactions, the role of salicylic acid
(SA) in activating defense related genes is well recognized
[1]. The SABP2 (Salicylic acid-binding protein 2) is
required to convert methyl salicylate to SA as part of the
signal transduction pathway that activates systemic
acquired resistance, induces PR expression, and enhances
disease resistance. Due to the reduced or absence of
genetic resistance to these pathogens in commercial
sweet orange cultivars, the genetic transformation to
over-express a gene involved in the defense response of
plants is a possible alternative to produce tolerant or
resistant plants to biotrophic pathogens.
Methods
The aim of this study was to produce ‘Hamlin’ sweet
orange (Citrus sinensis L. Osb.) transgenic plants, via
Agrobacterium tumefaciens, over-expressing the SABP2
gene from sweet orange driven by the constitutive pro-
moter ubiquitin (Ubq10). The SABP2 gene was cloned
into pCambia 2301 and inserted into A. tumefaciens
EHA 105. The genetic transformation was performed
using epicotyl segments from seedlings [2].
Results and conclusions
A total of 620 explants in three independent experi-
ments were introduced and approximately 336 shoots
were regenerated. The GUS histochemical test was
performed and confirmed the transformation of 30 posi-
tive shoots. These shoots are being grafted onto Carrizo
citrange [Citrus sinensis x Poncirus trifoliata (L.) Raf.]
seedlings grown in test tubes containing MS culture
medium. The presence of the transgene will be evalu-
ated by PCR using specifics primers that amplify part of
the ubiquitin promoter and part of the gene. SABP2
expression levels in transgenic plants will be assessed
through qPCR. After bud multiplication, transgenic
plants will be evaluated for their response to citrus can-
ker, HLB and leprosis.
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